Efficacy of Bimekizumab in the Management of Refractory Erythrodermic Pityriasis Rubra Pilaris: Clinical Insights

Sofia Theotokoglou; Dimitrios Sgouros; Konstantinos Theodoropoulos; Anna Syrmali; Georgia Pappa; Alexandros Katoulis

doi:10.5826/dpc.1503a5316

Efficacy of Bimekizumab in the Management of Refractory Erythrodermic Pityriasis Rubra Pilaris: Clinical Insights

Authors

Sofia Theotokoglou 2nd Department of Dermatology and Venereology, National and Kapodistrian University of Athens, Medical School, "Attikon" General University Hospital, Athens, Greece
Dimitrios Sgouros 2nd Department of Dermatology and Venereology, National and Kapodistrian University of Athens, Medical School, "Attikon" General University Hospital, Athens, Greece
Konstantinos Theodoropoulos 2nd Department of Dermatology and Venereology, National and Kapodistrian University of Athens, Medical School, "Attikon" General University Hospital, Athens, Greece
Anna Syrmali 2nd Department of Dermatology and Venereology, National and Kapodistrian University of Athens, Medical School, "Attikon" General University Hospital, Athens, Greece
Georgia Pappa 2nd Department of Dermatology and Venereology, National and Kapodistrian University of Athens, Medical School, "Attikon" General University Hospital, Athens, Greece
Alexandros Katoulis 2nd Department of Dermatology and Venereology, National and Kapodistrian University of Athens, Medical School, "Attikon" General University Hospital, Athens, Greece

Keywords:

Erythroderma, Bimekizumab, Pityriasis rubra pilaris, Refractory erythroderma treatment, Bimekizumab efficacy

References

Kromer C, Sabat R, Celis D, et al. Systemic therapies of pityriasis rubra pilaris: a systematic review. J Dtsch Dermatol Ges. 2019;17(3):243–259. DOI: 10.1111/ddg.13718. PMID: 30520557.

Kromer C, Schön MP, Mössner R. Treatment of pityriasis rubra pilaris with risankizumab in two cases. J Dtsch Dermatol Ges. 2021;19(8):1207–1209. DOI: 10.1111/ddg.14504. PMID: 33973380.

Napolitano M, Abeni D, Didona B. Biologics for pityriasis rubra pilaris treatment: a review of the literature. J Am Acad Dermatol. 2018;79(2):353–359.e11. DOI: 10.1016/j.jaad.2018.03.036. PMID: 29609014.

Feldmeyer L, Mylonas A, Demaria O, et al. Interleukin 23-Helper T Cell 17 Axis as a treatment target for pityriasis rubra pilaris. JAMA Dermatol. 2017;153(4):304–308. DOI: 10.1001/jamadermatol.2016.5384. PMID: 28122069.

Saad M, Bose R. Erythrodermic pityriasis rubra pilaris following SARS-CoV-2 vaccination treated with bimekizumab. JAAD Case Rep. 2023;42:7–11. DOI: 10.1016/j.jdcr.2023.09.024. PMID: 37961078.

Kromer C, Schön MP, Mössner R. Bimekizumab in refractory pityriasis rubra pilaris. J Dtsch Dermatol Ges. 2024;22(1):102–104. DOI: 10.1111/ddg.15252. PMID: 38066410.